Multimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorAnhui Provincial Hospital

About this trial

The purpose of this study is to construct and validate a multimodal survival prediction model by integrating 3D radiomics features derived from preoperative magnetic resonance imaging (MRI) with systemic clinical baseline indicators for patients with colorectal liver metastases (CRLM) after surgery. By combining micro-level radiomics signatures reflecting tumor micro-heterogeneity with macro-level clinical parameters (such as liver function and tumor biomarkers), the study aims to accurately evaluate individual post-operative prognostic risks. This quantitative tool will provide reliable decision support for clinicians to customize post-operative follow-up and personalized adjuvant treatment strategies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

The study population consists of adult patients diagnosed with colorectal liver metastases who underwent surgical resection across multiple participating clinical centers, featuring high-quality preoperative liver MRI scans and complete clinical follow-up histories.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • Multimodal Predictive Evaluation

    Procedure/Surgery

    Observational and non-invasive assessment based on preoperative MRI-derived 3D modeling and three-dimensional lesion reconstruction, combined with clinical parameters, to build a survival prediction model. No experimental intervention is assigned.

Treatment groups

205 Participants
are divided into 1 treatment group
Group A: CRLM Surgical Cohort1 intervention

Trial outcomes

Primary outcomes

1

Recurrence-Free Survival (RFS)

Recurrence-free survival (RFS) is defined as the time from the date of surgical resection to the date of first tumor recurrence (local, regional, or distant) or death from any cause, whichever occurs first.

Time frame
Up to 5 years post-surgery

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Anhui Provincial Hospital

Lead sponsor

Anhui Provincial Cancer Hospital

Collaborator